We’re proud to share that Alderley Lighthouse Labs (ALL) will play a key role in a major new initiative led by the University of Liverpool to accelerate the adoption of pharmacogenomics across the UK. As part of this collaborative project funded through Innovate UK as one of seven newly announced Centres of Excellence for Regulatory Science and Innovation (CERSIs). ALL will work alongside leading institutions to help shape the future of regulation in this rapidly evolving field. This milestone marks a major leap forward in our commitment to advancing pharmacogenomics and personalised medicine, reinforcing ALL’s role as a leader in UK healthcare innovation.
About the Project
The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics aims to explore how genetic variation influences the safety and effectiveness of medicines. Although pharmacogenomics holds enormous potential for personalised healthcare, its uptake in the NHS has been limited by the absence of clear regulatory guidelines. This initiative seeks to change that by building robust, evidence-based pathways for implementation of pharmocogenomics.
Our Role at ALL
As a commercial partner in the CERSI, ALL will help focus on developing innovative offerings in pharmacogenomic testing while sharing insights and data to support the broader regulatory framework. We’ll work alongside academic, industry, and regulatory stakeholders including the Medicines and Healthcare products Regulatory Agency (MHRA), Office for Life Sciences, and the Medical Research Council to accelerate safe and effective integration of pharmacogenomics into clinical care.
What This Means:
- Driving Innovation in Pharmacogenomics
With this support, ALL will help in the development of novel commercial solutions in pharmacogenomics, a field dedicated to understanding how genetic differences influence individual responses to medications. These innovations will help will help accelerate the delivery of pioneering personalised treatments, ensuring patients benefit from cutting-edge innovations. - Informing Future Regulation
Insights generated through this collaboration will not only fuel our commercial offerings but also contribute valuable data to help shape the regulatory landscape of pharmacogenomics. Together we aim to inform policy and best practices that ensure safe, effective use of genomic information in prescribing. - Enabling Personalised Prescribing Across the UK
This initiative is focused on enabling personalised prescribing. By aligning treatment plans with a patient’s genetic makeup, we can improve outcomes, reduce adverse drug reactions, and support a more proactive healthcare system.
Looking Ahead
This work will contribute to the national effort in bringing Pharmacogenomics to commercial laboratories, we will initially run assays from our new laboratory in Cheadle Greater Manchester, but the learnings will help regulators and others operate safely in this space.
Mark Wigglesworth CEO QUOTE “This initiative represents an exciting opportunity for ALL to help shape the future of personalised medicine and help bring pharmacogenomics from research labs into everyday clinical use. We are excited to contribute our expertise and innovation”.
Learn More
Explore the University of Liverpool’s article for a deeper look into this exciting new venture: New pharmacogenomics centre to help UK move towards personalised prescribing – Articles – Researcher Hub – University of Liverpool
We’re excited to embark on this journey and look forward to sharing more updates as this work unfolds.